Medivation board rejects Sanofi's $9.3 billion takeover offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation
May 3, 2016 7:27 AM EDTCredit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.
MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More
